Yourgene Health PLC YGS to support MHC's Boots agreement
May 22 2023 - 1:01AM
RNS Non-Regulatory
TIDMYGEN
Yourgene Health PLC
22 May 2023
Yourgene Health plc
("Yourgene", the "Group" or the "Company")
Yourgene Genomic Services to support MHC's Boots agreement
Manchester , UK - 22 May 2023: Yourgene (AIM: YGEN), a leading
international molecular diagnostic group, announces that its
partner MyHealthChecked plc (AIM: MHC) ("MyHealthChecked") has
entered into an agreement via its subsidiary Concepta Diagnostics
Limited with Boots UK Limited ("Boots"), the health and beauty
retailer and pharmacy group, to launch its extended range of
at-home self-testing products tests via boots.com and across 120
Boots stores in Great Britain and Northern Ireland.
Through the service agreement, five out of the 14 tests
MyHealthChecked are launching via Boots, will be processed by
Yourgene Genomic Services ("YGS") at the Company's accredited
laboratory in Manchester. The DNA cheek swab tests, that look at a
range of wellbeing factors such as glucose and weight management,
heart profiling, intolerance and sensitivities and finally vitamin
and minerals DNA testing, are already available online to purchase
via boots.com .
Lyn Rees, Chief Executive Officer of Yourgene, commented: "We
would like to congratulate our partner MyHealthChecked on their
retail launch with Boots of their extended product portfolio, which
demonstrates execution of the next step of their strategic plan.
Yourgene is proud to continue to support MyHealthChecked with our
state-of-the-art laboratory and the contract is a testament to the
quality of the service we provide."
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgenehealth.com
Joanne Cross, Director of Marketing
Walbrook PR Ltd (Media and Investor Relations) Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Paul McManus / Alice Woodings / Lianne Applegarth Mob: 07980 541 893 / 07407 804 654
/ 07584 391 303
About Yourgene Health
Yourgene Health is an international integrated technologies and
services business, enabling the delivery of genomic medicine. The
Group works in partnership with global leaders in DNA technology to
advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic and screening solutions,
for reproductive health and precision medicine. The Group's
portfolio of in vitro diagnostic products includes non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests and DPYD genotyping assays.
Building on our expertise in genomic technology, Yourgene's
Ranger(R) Technology offers next generation size selection with a
range of sample preparation platforms for dynamic target
enrichment. Ranger(R) Technology can be utilised to improve
workflows and performance in multiple applications including NIPT,
oncology, infectious disease testing and gene synthesis.
Yourgene Genomic Services offers a clinical service from UK and
Taiwan focusing on precision medicine and reproductive health,
including NIPT.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN".
For more information visit https://yourgenehealth.com/ and
follow us on twitter @Yourgene_Health.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained in this
announcement is of a non-regulatory nature. Information required to
be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on RNS Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAQKLFFXELXBBL
(END) Dow Jones Newswires
May 22, 2023 02:01 ET (06:01 GMT)
Premaitha (LSE:NIPT)
Historical Stock Chart
From Apr 2024 to May 2024
Premaitha (LSE:NIPT)
Historical Stock Chart
From May 2023 to May 2024